Cargando…

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Detalles Bibliográficos
Autores principales:	Wanner, Christoph, Cooper, Mark E, Johansen, Odd Erik, Toto, Robert, Rosenstock, Julio, McGuire, Darren K, Kahn, Steven E, Pfarr, Egon, Schnaidt, Sven, von Eynatten, Maximilian, George, Jyothis T, Gollop, Nicholas D, Marx, Nikolaus, Alexander, John H, Zinman, Bernard, Perkovic, Vlado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406051/ https://www.ncbi.nlm.nih.gov/pubmed/34476096 http://dx.doi.org/10.1093/ckj/sfab104

Ejemplares similares

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021)

SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA
por: Kahn, Steven, et al.
Publicado: (2019)

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
por: Perkovic, Vlado, et al.
Publicado: (2020)

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA(®)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
por: Rosenstock, Julio, et al.
Publicado: (2018)

Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial
por: Cooper, Mark E., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA(®) Trial
por: Watada, Hirotaka, et al.
Publicado: (2020)

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
por: Ruggenenti, Piero, et al.
Publicado: (2021)

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
por: McGuire, Darren K., et al.
Publicado: (2021)

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
por: Groop, Per-Henrik, et al.
Publicado: (2013)

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial
por: Espeland, Mark A., et al.
Publicado: (2020)

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
por: Fitchett, David, et al.
Publicado: (2019)

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(®))
por: Marx, Nikolaus, et al.
Publicado: (2015)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial
por: Groop, Per‐Henrik, et al.
Publicado: (2017)

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria
por: Cooper, Mark E., et al.
Publicado: (2019)

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
por: Johansen, Odd Erik, et al.
Publicado: (2012)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Chyluria Associated With Nephrotic-Range Proteinuria
por: Kaur, Amninder, et al.
Publicado: (2022)

Anti-Diabetic Agents and Heart Failure　― Response to the CARMELINA Study ―
por: Sano, Motoaki
Publicado: (2018)

Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA
por: Ghosh, Sujoy, et al.
Publicado: (2020)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
por: Biessels, Geert Jan, et al.
Publicado: (2018)

Tuberculosis infection in children with proteinuria/nephrotic syndrome
por: Szymanik-Grzelak, Hanna, et al.
Publicado: (2017)

Idiopathic Chyluria with Nephrotic-range Proteinuria and Hypothyroidism
por: Uzu, Takashi, et al.
Publicado: (2018)

Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study
por: Biessels, Geert Jan, et al.
Publicado: (2021)

Nephrotic-Range Proteinuria and Peripheral Edema in a Child: Not Only Idiopathic Nephrotic Syndrome
por: Dolcemascolo, Valentina, et al.
Publicado: (2016)

Nephrotic proteinuria and renal involvement in HIV-infected children
por: Shah, Ira
Publicado: (2011)

Microfilaria associated macroscopic hematuria and nephrotic range proteinuria
por: Prakash, G. K., et al.
Publicado: (2016)

Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2021)

Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation
por: Holmberg, Christer, et al.
Publicado: (2014)

ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome
por: Zhong, Fu, et al.
Publicado: (2022)

Involvement of Hemopexin in the Pathogenesis of Proteinuria in Children with Idiopathic Nephrotic Syndrome
por: Pukajło-Marczyk, Agnieszka, et al.
Publicado: (2021)

Primary Superior Lumbar Hernia with Nephrotic-range Orthostatic Proteinuria
por: Horino, Taro, et al.
Publicado: (2022)

Outcomes of minimal change disease without nephrotic range proteinuria
por: Son, Hyung Eun, et al.
Publicado: (2023)

Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia
por: Ji, Qiuhe, et al.
Publicado: (2021)

Nonsecretory Multiple Myeloma and AL Amyloidosis Presenting with Nephrotic Range Proteinuria
por: Beyler Kilic, Ozlem, et al.
Publicado: (2015)

Primary IgA nephropathy with nephrotic-range proteinuria in Chinese children
por: Zhao, Jing-Li, et al.
Publicado: (2021)

SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
por: Kalay, Zeynepgul, et al.
Publicado: (2022)

An Unexpected Finding in a Patient with AKI, Nephrotic Range Proteinuria, and MGUS
por: Scurt, Florian G., et al.
Publicado: (2023)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
por: Darsalia, Vladimer, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1jee6mtv7ojp241oahfau1eecv